Deepak Nitrite Ltd. moves to reshape its capital structure
TL;DR
What are the specific terms of the preference shares issued by Deepak Chem Tech to Deepak Phenolics—specifically the coupon rate, tenor, and redemption terms—and how do these terms compare to the cost of external debt currently being serviced by the subsidiary?
Deepak Chem Tech issued 1,24,00,000 9% Optionally Convertible Redeemable Preference Shares (OCRPS) to Deepak Phenolics for ₹124 Cr. The 9% coupon is confirmed, but the tenor and detailed redemption mechanics cannot be confirmed from the cited filing. [1]
Comparison with external debt: the cited material does not provide Deepak Chem Tech’s subsidiary-level external borrowing cost, interest expense, or effective interest rate. Therefore, it is not possible to determine whether the 9% preference-share coupon is cheaper or more expensive than the external debt currently being serviced.
The correct comparison would be between the 9% preference coupon and Deepak Chem Tech’s weighted-average effective borrowing rate, rather than Deepak Nitrite’s consolidated debt balance. The latter, even if available, would not establish the subsidiary’s cost of debt.
| Term | Reported detail |
|---|---|
| Coupon | 9% [1] |
| Tenor / maturity | Could not be confirmed |
| Redemption terms | The instrument is described as redeemable, but the redemption date, price/premium and applicable option mechanics could not be confirmed |
| Conversion feature | Optionally convertible; detailed conversion terms could not be confirmed [1] |
What is the stated mandate for Deepak Chem Tech (DCTL) within the group's capex roadmap, and how does this INR 124 Cr preference share infusion align with the specific project timelines or capacity expansion phases disclosed in the company's recent investor presentations?
DCTL’s stated mandate is to act as the group’s project vehicle for the integrated polycarbonate and specialty-chemicals expansion, including upstream intermediates and downstream BPA/polycarbonate capacity. The ₹124 Cr subscription is therefore best read as an internal funding tranche supporting DCTL’s execution and equity requirements—not as a separately announced new project or capacity milestone.
DCTL’s role in the capex roadmap
- Upstream integration: Management described the first phase as including nitric acid, MIBK, MIBC, nitration and hydrogenation assets; these were stated to be operational by August 2026. [2]
- Phase-I completion: The group’s rating disclosure said most Phase-I projects had been largely commissioned, with the balance expected to be completed in H1 FY27. [3]
- Downstream expansion: The next spending phase covers construction and licensing for polycarbonate, bisphenol A and other specialty-chemical projects. [2]
- BPA platform: DCTL’s board approved a greenfield BPA complex with capacity of up to 240 KTA and estimated investment of approximately ₹2,500 Cr. [4]
- Polycarbonate platform: The polycarbonate project remains targeted for commissioning in FY29, with full optimisation expected by FY31. The reported capex phasing was ₹2,200–2,400 Cr in FY28, approximately ₹2,500 Cr in FY29 and ₹2,500–3,000 Cr in FY30. [5]
How the ₹124 Cr fits
Deepak Chem Tech issued 1.24 crore 9% optionally convertible redeemable preference shares of ₹100 each to Deepak Phenolics, aggregating to ₹124 Cr. Both entities are wholly owned subsidiaries of Deepak Nitrite. [1]
The timing is consistent with funding the construction and equity phase of DCTL’s downstream projects:
- The broader propylene/polycarbonate programme was described as an approximately ₹11,500 Cr project funded in a 60:40 debt-equity mix, with debt already tied up. [6]
- Management had earlier indicated that equity would be contributed before the associated bank debt was drawn. [7]
- Against the ₹11,500 Cr envelope, the ₹124 Cr infusion represents approximately 1.1%, derived from the disclosed amounts. This indicates a tranche of the overall funding plan rather than the financing of the entire BPA or polycarbonate project. [1] [6]
Analyst read
The infusion aligns most closely with the transition from largely commissioned upstream assets to the construction-heavy downstream phase—particularly BPA, polycarbonate and related specialty chemicals. It can strengthen DCTL’s internal capital base while project expenditure continues and debt funding is drawn.
However, a project-specific earmark for the ₹124 Cr could not be confirmed. The transaction announcement identifies the instrument and recipient but does not establish that the money was allocated specifically to the 240 KTA BPA project, the FY29 polycarbonate commissioning phase, or the residual Phase-I work. Accordingly, the strategic fit is clear, but the exact project linkage remains unquantified.
How does this inter-company capital allocation via preference shares compare to the funding structures historically used for Deepak Phenolics' own capacity expansions, and does this shift indicate a group-level preference for internal equity-like funding over external debt for new project vehicles?
Verdict: The ₹124 Cr preference-share subscription is an internal, equity-layer funding mechanism for a project vehicle, but it does not demonstrate a group-wide shift away from external debt. The disclosed financing pattern remains mixed: internal group funding has supported earlier expansion phases, while the large integrated propylene–polycarbonate programme is explicitly structured with substantial bank debt.
The OCRPS structure is therefore best interpreted as internal hybrid capitalisation of DCTL. Because DPL and DCTL are both wholly owned subsidiaries, the transaction brings no third-party capital into the consolidated group; it reallocates capital between legal entities while strengthening DCTL’s standalone funding base [1]. The filing does not establish whether the ₹124 Cr specifically forms part of the equity contribution required under the bank financing arrangement.
The comparison with Deepak Phenolics’ own capacity expansions is less definitive. A project-by-project historical financing mix for DPL’s standalone capacity additions could not be confirmed from the cited material. The closest disclosed evidence points to a two-layer model: Group internal accruals funded earlier project activity, while the much larger current expansion uses internal equity plus external bank debt.
At scale, the ₹124 Cr subscription is also modest relative to the approximately ₹11,500 Cr integrated project—about 1.1%, derived from ₹124 Cr [1] divided by ₹11,500 Cr [6]. That makes it more consistent with targeted capital support for a new vehicle or a specific funding milestone than with a wholesale change in group financing policy.
Implication: The group appears to prefer putting internal capital behind new project vehicles before, or alongside, external borrowing. That can preserve control and help satisfy lenders’ equity requirements, but the evidence supports “internal equity-like funding plus debt”, not “internal funding instead of debt.” The 9% coupon also means the OCRPS should not be treated as cost-free common equity.
_Scope note: this comparison also included Aether Industries Limited (AETHER); Fine Organic Industries Limited (FINEORG); Aarti Industries Ltd. (AARTIIND); Anupam Rasayan India Limited (ANURAS); Atul Ltd. (ATUL), which the answer above does not cover. Ask about any of them for a full side-by-side._
| Funding episode | Reported structure | Analyst reading |
|---|---|---|
| DPL investment in DCTL, 20 November 2026 | DPL subscribed ₹124 Cr of 9% optionally convertible redeemable preference shares issued by DCTL; both are wholly owned subsidiaries of Deepak Nitrite [1] | Internal capital transfer with hybrid characteristics: more equity-like than a bank loan, but with a 9% coupon and redemption/conversion features |
| Earlier expansion phase under DCTL | Project-cost increases were described as funded through Group internal accruals [3] | Evidence of internal self-funding for at least part of the expansion cycle |
| Integrated propylene–polycarbonate project, including the linked phenol expansion | Approximately ₹11,500 Cr project funded in a 60:40 debt-equity ratio, with the debt already tied up [6] | External debt remains a central funding source, rather than being replaced by internal preference capital |
| Debt drawdown sequence | Management stated that equity was being contributed first and bank debt would be drawn after the required equity contribution [7] | Internal capital is being used as the equity tranche or bridge to debt funding, not necessarily as a substitute for debt |
Sources
- [1]Deepak Phenolics Invests INR 124 Cr in Deepak Chem Tech via Preference Shares — 2026-11-20T16:32:00, p.1
- [2]Vadodara-based Deepak Nitrite expects strong FY27 as raw material strategy supports growth - CNBC TV18 — CNBC TV18, 2026-08-07T00:00:00
- [3]Deepak Phenolics Limited: Ratings reaffirmed — Icra, 2026-08-27T00:00:00
- [4]Deepak Nitrite Q1 profit surges as margin doubles; board clears ₹2,500 crore expansion - CNBC TV18 — CNBC TV18, 2026-08-04T00:00:00
- [5]Deepak Nitrite Ltd. - Result Update – 06 November 2026 — Way2Wealth, 2026-11-06T00:00:00
- [6]Deepak Nitrite Limited Q1 FY27 Earnings Conference Call August 06, 2026 — Deepak Website Prd, 2026-08-11T00:00:00
- [7]Deepak Nitrite Limited Q4 & FY26 Earnings Conference Call Transcript — May 18, 2026 — BSE India, 2026-05-22T00:00:00
Keep digging